Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Stop Worrying about the Cost of Ransomware with Cyvatar

Cyvatar

Cyvatar today announced that it has partnered with Cysurance, a next-generation platform delivering cyber insurance as a service to growing businesses, to offer an enhanced service guarantee as a benefit to all customers with a silver membership or higher. Starting today, Cyvatar members can worry less about the high costs associated with ransomware or business email compromise (BEC) attacks, regulatory fines, cyber legal liability, and more. With a Cyvatar Silver, Gold, or Enterprise subscription, members benefit from an exclusive service guarantee that pays for up to $500,000 of breach-related costs. “The partnership with Cysurance gives Cyvatar members a financial safety net in the event of a successful attack,” said Kirsten Bay, Cysurance co-founder and chief executive officer. “The added protection will enable them to manage all types of cyber risk.” Cyvatar already guarantees members of all levels a fully remediated, continuously clean security environment within the first 90 days. Now, that guarantee extends to service disruption costs related to: Ransomware threats Business email compromise Compliance penalties, audit failures, and regulatory fines Cyber legal liability expenses Business Interruption costs “We’re proud to partner with Cysurance and offer our members a one-of-a-kind security experience, one where they can get CyValue fast,” said Cyvatar Co-Founder and CEO Corey White. “As we continue to grow and evolve our revolutionary cybersecurity-as-service (CSaaS) offering, we have the opportunity to add more exciting benefits for our members all for the same fixed subscription price they pay today.” Cyvatar’s enhanced service guarantee comes bundled with all memberships starting at the Silver subscription level. In addition to breach cost assurance, the membership also includes: Click here to learn more about Cyvatar and Cysurance’s new partnership and sign up for Cyvatar’s robust membership offering today. About Cysurance Cysurance is the next-generation cyber solution, protecting small businesses and their partners through affordable cyber risk management. Built on a proprietary platform, our program comes with a complete set of features to safeguard business continuity and insure against loss, protecting both revenue and recovery. For more information, visit www.cysurance.com, follow us on LinkedIn, Facebook, and Twitter, or email us at info@cysurance.com. Insurance and 360Protect offered by Cysurance, LLC. NY License #1578397. All products may not be available in all states. This communication contains product summaries only. Coverage or protection is subject to the language of the policies and terms as actually issued. Nothing in this communication should be construed as involving the sale, solicitation or negotiation of insurance, the provision or offer of insurance services, or the provision or offer of legal advice or services. About Cyvatar Cyvatar is committed to effortless cybersecurity for everyone. As the industry’s first subscription-based, cybersecurity-as-a-service (CSaaS) company, it’s our mission to transform the way the security industry builds, sells, and supports cyber solutions. We empower our members to achieve successful outcomes by providing expert practitioners, market-leading technologies, and proven best practices to guarantee business results. Our approach is rooted in a proprietary ICARM (installation, configuration, assessment, remediation, maintenance) methodology that delivers measurable security solutions for superior compliance and cyber-attack prevention, all bundled into a fixed monthly subscription that members can cancel anytime. Cyvatar is headquartered in Irvine, California, with locations around the world. Begin your journey to security confidence at cyvatar.ai and follow us on LinkedIn and Twitter. Contact Details Cyvatar KC Higgins +1 303-434-8163 kc@cyvatar.ai Cysurance Gray Newhouse +1 917-503-8031 Company Website https://cyvatar.ai/

September 13, 2021 08:00 AM Eastern Daylight Time

American Kidney Fund Brings Renal Community Together with Virtual Kidney Action Week, Sept. 13-17

American Kidney Fund

The American Kidney Fund (AKF) will host its second annual virtual Kidney Action Week from Monday, Sept. 13 to Friday, Sept. 17. The free, five-day event will bring together patients, medical experts and advocates for 14 sessions throughout the week that will focus on healthy living in the face of kidney disease, with an emphasis on confronting health disparities. Kidney Action Week is made possible by the generosity of sponsors Boehringer Ingelheim, Otsuka America Pharmaceutical, Inc. and US Renal Care. Kidney Action Week is open to the public, and more than 2,000 people have already registered to participate. For the full schedule of events, details and to register, visit KidneyActionWeek.org. “People with kidney disease are looking for accurate, up-to-date health information and they’re looking for support as they fight to live their healthiest lives in the face of this serious, complex disease,” said LaVarne A. Burton, AKF President and CEO. “We’re incredibly grateful to the sponsors, health experts and advocates from around the country who are joining us throughout the week to engage the kidney community in a virtual conversation about so many of the aspects of kidney disease—from prevention, to management, to dialysis and transplant.” More than 37 million Americans have kidney disease, which presents no symptoms until the late stages and is among the top 10 causes of death in the country. More than 785,000 Americans are living with kidney failure, which is treatable only by dialysis or transplant. Health disparities will be an overarching theme throughout Kidney Action Week and will be the focus of AKF’s virtual Congressional briefing on Sept. 15. People of color are disproportionately affected by kidney failure and often face barriers to early diagnosis and effective treatments that enable them to slow or stop the progression of the disease, as well as barriers to kidney transplant. Kidney Action Week will feature live sessions during which participants can ask questions of experts in nephrology, renal nutrition and more. AKF is grateful to session sponsors AstraZeneca, Alexion Pharmaceuticals, GSK, Horizon Therapeutics plc, Natera, Sanofi Genzyme, Travere and Vertex Pharmaceuticals. Kidney Action Week session highlights include: Monday, Sept. 13 10 a.m. ET – Finding Answers for the Unknown Causes of Kidney Disease: A Roadmap for Change panel discussion 3 p.m. ET – The Importance of Clinical Trials: Why Participant Diversity Makes a Difference panel discussion Tuesday, Sept. 14 10 a.m. ET – Home Dialysis and the Patient Experience: Could Home Dialysis be for You? panel discussion 12:30 p.m. ET – Know Your Kidney Health Care Team: Effective Communication for the Best Health Outcome panel discussion 3 p.m. ET – Living with Stage 3 Kidney Disease panel discussion Wednesday, Sept. 15 10 a.m. ET – Ask a Nephrologist Q&A with Dr. Akhtar Ashfaq, member of AKF’s Medical Advisory Committee 1 p.m. ET – AKF’s Congressional briefing, Increasing Kidney Transplants in Communities of Color, will focus on the challenges of health disparities and what can be done to increase the number of transplants among people of color. 2:30 p.m. ET – Ask the Expert Q&A with Dr. Blake Shusterman, AKF Kidney Kitchen ® partner also known as The Cooking Doc ® Thursday, Sept. 16 10 a.m. ET – Gout & Kidney Disease panel discussion 3 p.m. ET – The Kidney Transplant Process: What You Need to Know panel discussion Friday Sept. 17 10 a.m. ET – Life After a Kidney Transplant panel discussion 12:30 p.m. ET – Kidney Disease & Mental Health panel discussion Kidney Action Week is part of AKF’s Know Your Kidneys™ kidney disease education and prevention program. In 2020, AKF transformed its signature community kidney disease prevention event, Kidney Action Day, into Kidney Action Week. Kidney Action Week 2020 was a first-of-its-kind event in the COVID-19 era, providing a virtual space to focus on kidney health and kidney disease awareness and prevention for people nationwide. About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details Stefanie Tuck Work: +1 202-470-1797 Mobile: +1 978-390-1394 11921 Rockville Pike, Suite 300, Rockville, MD 20852 AKF@jpa.com Company Website http://www.kidneyfund.org/

September 13, 2021 08:00 AM Eastern Daylight Time

Corporate and Individual Donors Step Up to Support American Kidney Fund Hurricane Ida Disaster Relief Program

American Kidney Fund

When Hurricane Ida hit Louisiana on August 29, the American Kidney Fund (AKF) mobilized its longstanding Disaster Relief Program to help kidney patients in crisis, providing $22,000 to more than 110 dialysis and post-transplant patients facing critical needs. This support has been made possible by generous donations from the public, Chinook Therapeutics, Inc. and other corporate supporters. Power outages, evacuations and temporary dialysis clinic closures put kidney patients in extremely challenging circumstances, on top of the immediate threat of the storm. Contributions to AKF’s Disaster Relief Program are making it possible for AKF to support patients with emergency grants of $200 each to help them replace lost medications and special renal diet foods, pay for temporary housing and transportation to treatments, and replace clothing and personal essentials lost due to the disaster or the need to evacuate with short notice. Louisiana dialysis and recent kidney transplant patients who need emergency financial help should contact a social worker at their dialysis clinic for information on applying for aid or apply directly at gms.KidneyFund.org. “We are very grateful to Chinook Therapeutics and our many other supporters for their generosity that has made emergency relief possible for so many Louisianans struggling to remain safe, while continuing their life-sustaining treatments,” said LaVarne A. Burton, AKF President and CEO. “Disasters like Hurricane Ida are particularly challenging for people with kidney failure, especially when they hit in the middle of a pandemic that has put these patients at increased risk for severe illness from COVID-19 for the past year and a half. We thank the supporters who are enabling us to provide this much-needed assistance.” AKF is covering 100% of the cost of emergency grant processing and check distribution to ensure that the maximum number of patients can receive desperately needed support. AKF expects the number of grant requests to increase in the coming weeks as Louisianans regain power, cell service and access to basic everyday needs, and can begin to return home and to their regular dialysis clinics. Charity Navigator has listed AKF as one of the highly rated nonprofits providing Hurricane Ida relief. AKF is one of only three nonprofits in the nation to have received the top 4-Star rating from Charity Navigator for 19 consecutive years—every year the organization has been rating nonprofits—giving donors the confidence that their contributions will be used to maximum efficiency. To make a contribution to AKF’s Disaster Relief Program to assist kidney patients affected by Hurricane Ida, visit AKF’s online donation page. ### About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details Stefanie Tuck Work: +1 202-470-1797 Mobile: +1 978-390-1394 11921 Rockville Pike, Suite 300, Rockville, MD 20852 AKF@jpa.com Company Website http://www.kidneyfund.org/

September 03, 2021 01:34 PM Eastern Daylight Time

NextFerm Technologies Obtains US Regulatory Marketing Approval for Astaferm® Astaxanthin Antioxidant, in Oil for Soft-Gels

NextFerm Technologies Ltd.

NextFerm Technologies (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, yeast-based, non-GMO protein alternative and other innovative yeast-based nutrients, today announced receipt of regulatory marketing approval (Self-GRAS) for Astaferm®, its innovative fermented astaxanthin antioxidant in the form of Oil for Soft-Gels, in the US. Astaferm® is already sold in the US and Canada in the form of Gummies and powder by well-established Brands in North America. NextFerm expects initial Purchase orders for the oil during 2021. NextFerm currently prepares to expand the marketing of Astaferm® for additional indications such as immune system support, as well as expanding into additional serving forms, such as water-dispersible powder for food and beverages. Boaz Noy, Chief Executive Officer of NextFerm, said, “ Soft-Gels is the most popular form of consumption of Astaxanthin. This marketing approval allows NextFerm to expand its value proposition in the market, while increasing market awareness and offer fermented Astaxanthin in the form of oil with a competitive price, in addition to Astaxanthin in Gummies. we believe it will contribute to revenues growth in the coming quarters.” About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein alternative with nutritional value that is similar to animal-derived protein and a neutral flavor, with no aftertastes that are typical of plant-based protein. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at $13 billion, with an annual growth rate of 10%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. NextFerm is gearing up for commercialization of the product in the US in 2022. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. In July 2021, the Company received Regulatory Marketing Approval for Astaferm® in Canada. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details Nextferm Technologies Ltd. Yossi Ohana - Chief Financial Officer +972 54-771-5893 yossio@nextferm.com Investor and Media contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com Company Website https://www.nextferm.com/

September 02, 2021 02:29 PM Eastern Daylight Time

The Meningitis Vaccines: What Parents of Adolescents Should Know

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/OpbXUBrzUA4 According to the CDC, COVID-19 disrupted routine well-child visits for many children over the last year. As a result, too many children have fallen behind on receiving recommended vaccines – and that includes adolescents and young adults. If young adults are not receiving these recommended vaccinations, they are now vulnerable to infectious, potentially deadly diseases. So are the campuses and communities they live in. One vaccine that often gets left behind is Meningitis B, which is recommended for adolescents 16-23 years old. There are two types of meningitis vaccines – MenACWY and MenB. Few have received the MenB vaccine, yet it’s responsible for 100% of meningococcal meningitis outbreaks on college campuses since 2011. One issue? A lack of communication from pediatricians and family physicians. A recent study found that 49% of pediatricians and 69% of family physicians did not discuss the MenB vaccine during routine visits for 16-18-year-olds. That’s one reason why research shows that nearly 80% of parents did not know about the MenB vaccine, and why more than 78.2% of 17-year-olds have not received at least one dose of the Meningitis B vaccine. As kids head back to school, it’s important that parents take the time to check what vaccinations their teens and young adults have received and proactively talk to their healthcare provider about what other vaccines they need – including both the MenACWY and MenB meningitis vaccines. For more information visit: https://meningitisbactionproject.org/ About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 02, 2021 01:00 PM Eastern Daylight Time

Video

Broadcom MASTERS Announces the Top 300 Middle School Innovators in National STEM Competition

Society for Science

WASHINGTON, DC – Broadcom Foundation and Society for Science today announced the Top 300 MASTERS in the 10th annual Broadcom MASTERS ® — the nation’s premier Science, Technology, Engineering and Math (STEM) competition for middle school students. The Broadcom MASTERS, a program of the Society for Science, seeks to inspire young scientists, engineers and innovators to solve the grand challenges of the 21 st century. Each of the Top 300 MASTERS will receive a $125 award from DoD STEM. With this prize, now in its second year, the Department of Defense continues its support of youth in STEM, working towards a more diverse pipeline of highly qualified STEM professionals in the future. The Top 300 MASTERS were selected from 1,841 students from 48 states, Washington, DC and three US territories (Puerto Rico, Guam and Virgin Islands) applying to be a Broadcom MASTER. Only students who are named in the top 10% of their science fair are eligible to enter the Broadcom MASTERS, which is the only middle school STEM competition that leverages Society-affiliated science fairs as a critical component of the STEM talent pipeline. The Top 300 Broadcom MASTERS include: 58.7% of the Top 300 MASTERS identify as girls while 40.3% identify as boys. The MASTERS come from 41 states and Guam, a US territory. The state with the most MASTERS is California, with 23% or 69 students. Florida follows with 31 students (10.3%), then Texas at 22 (7.3%), Pennsylvania 20 (6.67%) and Oregon 18 (6%) The top two project categories are Earth and Environmental Sciences (42) and Behavioral and Social Sciences (38) More than 2/3 of the MASTERS (206) go to public school, with 59 (19.7%) in private school and 15 (5%) in charter schools. The remaining students are in home, magnet or online schools. The students’ names and a state-by-state breakdown of the Top 300 Broadcom MASTERS can be found at https://www.societyforscience.org/broadcom-masters/2021-top-300-masters/. Thirty of the top 300 Broadcom MASTERS will be selected as finalists by a panel of scientists, engineers and educators from around the nation. The 30 finalists, who will be announced September 14, will be competing for over $100,000, including the coveted $25,000 Samueli Prize, $10,000 DoD STEM Talent Award, the $10,000 Lemelson Award for Invention, the $10,000 Marconi/Samueli Award for Innovation and the $10,000 Robert Wood Johnson Foundation Award for Health Advancement. “Congratulations to the 300 Broadcom MASTERS,” said Maya Ajmera, President and CEO of the Society for Science and Publisher of Science News. “These students have shown tremendous grit and perseverance by conducting scientific or engineering research during a worldwide pandemic. Their curiosity and determination is inspiring for all.” The Top 300 Broadcom MASTERS’ independent STEM research projects tackle a broad range of challenges such as: The efficiency of solar panels Early detection of algal blooms Circumventing ventilator shortages Using machine learning to detect heart arrhythmias Data security Face mask effectiveness “Those of you in the Top 300 are exemplars of all young people who aspire to become scientists, engineers and innovators in Society-affiliated science fairs,” said Paula Golden, President of the Broadcom Foundation. “The Broadcom MASTERS serves as an important milestone in your STEM journey. Middle school is a time when many students gain confidence needed to follow their passions; and the accomplishment of being selected as one of the Top 300 is something for which each and every one of you should be enormously proud.” In addition to the $125 cash prize, the Top 300 Broadcom MASTERS will receive a prize package containing an award ribbon; semifinalist certificate of accomplishment; Broadcom MASTERS backpack; a Broadcom MASTERS decal; a specialized Invention Journal, courtesy of The Lemelson Foundation; a one-year subscription to Wolfram|Alpha Notebook Edition, courtesy of Wolfram Research; a special prize from Jeff Glassman, CEO of Covington Capital Management; and a one-year family digital subscription to Science News magazine. In recognition of the role that teachers play in the success of their students, each designated teacher also will receive a Broadcom MASTERS tote bag; a special edition booklet of Science News for Students’ Invention & Innovation articles from The Lemelson Foundation; and a one-year digital subscription to Science News magazine. Resources: For more information on the Broadcom MASTERS, visit the Broadcom Foundation and Society for Science. To keep up with the Broadcom MASTERS, use hashtag #brcmMASTERS or follow Broadcom Foundation and the Society on Twitter or the Society on Instagram. And to stay connected, visit the Broadcom MASTERS and Society Facebook pages. You can also follow the Society on Snapchat (Society4Science). About Broadcom Foundation Founded in April 2009, the Broadcom Foundation is a 501(c)(3) nonprofit corporation with its main mission to advance science, technology, engineering and math (STEM) education by funding research, recognizing scholarship and increasing opportunity. The foundation inspires young people to pursue careers in STEM through its signature programs, the Broadcom MASTERS® and the Broadcom MASTERS® International, premier science and engineering competitions for middle school students around the United States and the world. Learn more at www.broadcomfoundation.org/masters. About Society for Science Society for Science is dedicated to the achievement of young scientists in independent research and to public engagement in science. Established in 1921, the Society is a nonprofit whose vision is to promote the understanding and appreciation of science and the vital role it plays in human advancement. Through its world-class competitions, including the Regeneron Science Talent Search, the International Science and Engineering Fair and the Broadcom MASTERS, and its award-winning magazines, Science News and Science News for Students, Society for Science is committed to inform, educate, and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram and Snapchat (Society4Science). Contact Details Gayle Kansagor +1 703-489-1131 gkansagor@societyforscience.org Company Website https://www.societyforscience.org/

September 01, 2021 12:02 PM Eastern Daylight Time

YuMOVE Offers Tips for Walking Your New Pandemic Puppy

Lintbells

For many across the country, new work from home policies, quarantines, social distancing, and loneliness all added to the appeal of adding a new puppy to the home. Whether the timing was right for a pandemic puppy or owners had been planning on a new puppy for a while, there’s no doubt pet ownership is on the rise. Bringing a puppy home for the first time can be exciting, with owners anxious to get out for ‘walkies’ as soon as possible. But too much exercise especially high-impact exercise, can be bad for puppies and increase the chance of broken bones. “When a puppy is born, its bones are not fully formed,” said Veterinarian Dr. Craig Prior, B.V.Sc., C.V.J., member of YuMOVE veterinary advisory board. “The age at which the growth plates close or stop growing varies hugely between individuals, breeds and joints, but tends to be somewhere between six months and two-and-a-half years, with an average of about a year. Some studies have suggested that too much exercise before these growth plates close can put strain on joints and increase the risk of various bone and joint conditions.” Here’s a helpful chart to reference before taking your puppy out. Other tips to keep in mind when walking puppies include: Walk don’t run – Until your puppy is fully grown, avoid taking them for a jog, cycle ride, or any other type of vigorous exercise. Pay attention- While you’re walking, pay attention to your puppy, and stop if you notice them getting tired – even if it’s been less than the recommended exercise time. Vaccinations- avoid other dogs and public areas until 5-7 days after vaccination round two to keep them from getting sick. Heat- puppies, like adult dogs and humans, can be at risk for heatstroke if temperatures get too hot. Keep puppies inside if the temperature exceeds 90 degrees and pay attention to the pavement temperature as the ground can get much hotter than the surrounding air. Hold the back of your hand to the pavement for 10 seconds. If you can’t hold for the full amount, it’s too hot for your puppy as well. Play- Gentle tug of war games and rolling a ball slowly for your pup is okay, but Charging after a ball that has been thrown, or excessive rough and tumble with a larger dog should be avoided. Pet owners should talk with their veterinarian about any questions or concerns with their puppy’s activity or growing hips/joints. Being proactive and taking steps to optimize the health of your younger dog once they get to be about three years of age is a good thing as well! It means they’ll be less likely to develop problems with stiffness and mobility as they grow older. Supplements can be used by younger dogs- not recommended for use on puppies- but be sure to look for a product designed especially to support active and growing joints such as YuMOVE Young & Active joint support for dogs 5 years and younger. Interviews, additional veterinarian advice and supporting documentation available upon request. For more information on hip/joint health and keeping pets active for life, please visit https://yumove.com/blogs/health-guides. About YuMOVE YuMOVE is clinically proven* and the #1 hip and joint supplement in the UK** now available in the US. YuMOVE is on a mission to keep pets ‘active for life’ which is why we are committed to making the best joint support products in the world. Packed with unique ActivEase® Green Lipped Mussels, sustainably sourced from select New Zealand bays, YuMOVE is full of antioxidants and Omega 3. Its unique premium formula aids joint development supports active joints and structure and promotes mobility. www.yumove.com *Study conducted by the Royal Veterinary College of London, United Kingdom **Kynetec VetTrak data, sales through veterinary wholesalers, February 2021 About Lintbells Lintbells, the UK's #1 Vet Recommended Dog Joint Supplement company, currently helps more than 1 million dogs across Europe and the United States. In March 2019, Lintbells officially entered the US Market with the introduction of their most popular product abroad, YuMOVE Soft Chews. This joint supplement promotes joint and cartilage health in dogs of all breeds and sizes. Made from all-natural, human-grade, non-GMO ingredients, the secret to YuMOVE Soft Chews' success comes from Lintbells own ActivEaseÂ® Green Lipped Mussel (or GLM). GLM, a superfood derived from the purest sources in New Zealand, is an essential ingredient with extraordinary properties that improves joint function, mobility, and reduces discomfort in our dogs. This unique ingredient, rich with more Omega 3s than any other GLM, is naturally anti-inflammatory, meaning our dog's stiff joints are eased naturally. To learn more, visit www.yumove.com Contact Details Jamie Baxter +1 775-322-4022 jamie@theimpetusagency.com Company Website https://yumove.com/

August 31, 2021 10:31 AM Pacific Daylight Time

American Kidney Fund Activates Disaster Relief Program to Support Dialysis and Post-Transplant Patients Affected by Hurricane Ida

American Kidney Fund

The American Kidney Fund (AKF), the leading nonprofit working on behalf of 37 million Americans living with kidney disease, has activated its Disaster Relief Program to provide $200 emergency grants to dialysis and post-transplant patients in Louisiana who have been affected by Hurricane Ida, which made landfall on Sunday as a category 4 hurricane. AKF’s Disaster Relief Program is the nation’s only rapid-response system that provides emergency financial assistance to dialysis and recent transplant patients. When disaster strikes their communities, AKF disaster relief grants help kidney patients replace lost medications and special renal diet foods, pay for temporary housing and transportation to treatment, and replace clothing and personal essentials lost due to the natural disaster or the need to evacuate with short notice. Louisiana dialysis and recent kidney transplant patients who need emergency financial help should contact a social worker at their dialysis clinic for information on applying for aid or submit an application directly at gms.KidneyFund.org. “Natural disasters, such as Hurricane Ida, create further challenges for dialysis and post-transplant patients on top of keeping themselves and their families safe, such as making arrangements to continue receiving their life-sustaining treatments,” said LaVarne A. Burton, AKF President and CEO. “With individual resources already spread thin 18 months into the COVID-19 pandemic, the impact of these natural disasters could be devastating for many. Our Disaster Relief Program helps to relieve some of the financial burdens patients face in the wake of disaster.” AKF’s website provides emergency resources for patients effected by Hurricane Ida. AKF additionally has general emergency preparedness information for dialysis and post-transplant patients at KidneyFund.org/disaster-prep. This page includes information about the 3-Day Emergency Diet Plan for dialysis patients. By following this plan, kidney patients can help reduce waste buildup in their bodies if they have to miss or delay their dialysis treatments. AKF has been providing emergency disaster financial assistance to kidney patients throughout all the major disasters that have struck the United States and its territories for the past two decades. In 2020, AKF provided $62,000 in disaster relief grants to 333 patients affected by Hurricanes Laura and Sally and the Oregon wildfires. AKF also activated its Coronavirus Emergency Fund in March 2020 and has provided over $3.1 million in assistance to nearly 13,000 low-income dialysis and transplant patients during the pandemic. To make a contribution to AKF’s Disaster Relief Program to assist kidney patients affected by Hurricane Ida, visit AKF’s online donation page. 100% of all donations go directly to patients affected by Hurricane Ida. AKF is covering the cost of grant processing and check distribution to ensure that the maximum number of patients in need receive the support they so desperately need. About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details Stefanie Tuck +1 202-470-1797 11921 Rockville Pike, Suite 300, Rockville, MD 20852 AKF@jpa.com Company Website https://www.kidneyfund.org

August 30, 2021 01:31 PM Eastern Daylight Time

Elsevier appoints health analytics industry leader Josh Schoeller as President, Clinical Solutions

Elsevier

Elsevier, a global leader in research publishing and information analytics, announced today that Josh Schoeller has been appointed President of its Clinical Solutions business unit, which serves healthcare professionals around the world by providing evidence-based content, health analytics and digital solutions to help improve patient outcomes. Mr. Schoeller has more than 30 years of experience leading and scaling businesses focused on Big Data, predictive analytics, application architecture, and decision support to advance patient care and quality improvements across healthcare. Since 2018 Mr. Schoeller has served as CEO of the healthcare business of Lexis Nexis Risk Solutions, part of RELX. He will maintain his CEO responsibilities for Healthcare at LexisNexis Risk Solutions in addition to his leadership role with Clinical Solutions. Jan Herzhoff, President, Health at Elsevier said: “Josh has a strong track record of success working across multiple segments in healthcare and building high-performing organizations. We are thrilled to have Josh’s leadership and look forward to exploring additional synergies between the healthcare business of LexisNexis Risk Solutions and Clinical Solutions, especially in the field of advanced provider analytics, which is a key area of focus for Elsevier.” Mr. Schoeller joined LexisNexis Risk Solutions in 2013 through the acquisition of Enclarity. While at Enclarity, he served as the Vice President, Chief Solution Architect responsible for delivering industry-leading provider data management solutions for healthcare providers. Prior to this role, he spent 15 years at FICO, a data analytics company, where he held diverse roles in information technology, sales and operations. Mr. Schoeller currently serves on the Board of the eHealth Initiative and Foundation (eHI) and is a member of the Forbes Business Development Council. Mr. Schoeller added: “At the heart of improving healthcare is effectively applying outcomes-driven analytics across the care continuum. I’m excited about the tremendous opportunity to combine the market-leading evidence-based content and clinical reference and workflow solutions of Elsevier Health with our differentiated data and analytics capabilities to support healthcare providers in delivering better outcomes for patients.” Elsevier’s Clinical Solutions business brings evidenced-based content into the care process, empowering healthcare professionals, as well as patients, to make better decisions. Serving over 2,000 healthcare organizations, Elsevier's clinical and technology experts are at the forefront of helping their customers leverage evidence-based content in the EMR and at the point of care. To learn more, visit Elsevier. --- About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Teresa Mueller, Vice President, Global Health Markets +31 6 20987384 t.mueller@elsevier.com Company Website https://www.elsevier.com/en-xs

August 30, 2021 08:00 AM Eastern Daylight Time

Image

1 ... 210 211 212 213 214 ... 249